Literature DB >> 15452731

Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells.

Steven De Vleeschouwer1, Stefaan W Van Gool, Frank Van Calenbergh.   

Abstract

REVIEW: In this review, we discuss immunotherapy for malignant gliomas. EMPHASIS: The emphasis is on the novel strategy of active specific immunotherapy using dendritic cells as antigen-presenting cells, especially its theoretical concepts and advantages, specific requirements, critical issues, pre-clinical and early clinical experience. Dendritic cell vaccination is situated in the diversity of other immunotherapeutical approaches. FURTHER DISCUSSION: Future directions, challenges, and drawbacks will be discussed.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15452731     DOI： 10.1007/s00381-004-0994-3

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN： 0256-7040            Impact factor:   1.475


  127 in total

Review 1.  Dendritic cells: specialized and regulated antigen processing machines.

Authors:  I Mellman; R M Steinman
Journal:  Cell       Date:  2001-08-10       Impact factor: 41.582

2.  Dendritic cells: On the move from bench to bedside.

Authors:  F O Nestle; J Banchereau; D Hart
Journal:  Nat Med       Date:  2001-07       Impact factor: 53.440

3.  Survivin in brain tumors: an attractive target for immunotherapy.

Authors:  Masahito Katoh; Rick Wilmotte; Marie-Claude Belkouch; Nicolas de Tribolet; Gianpaolo Pizzolato; Pierre-Yves Dietrich
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

4.  Expression of the tumor-rejection antigen SART1 in brain tumors.

Authors:  T Imaizumi; T Kuramoto; K Matsunaga; S Shichijo; S Yutani; M Shigemori; K Oizumi; K Itoh
Journal:  Int J Cancer       Date:  1999-12-10       Impact factor: 7.396

5.  Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report.

Authors:  L M Liau; K L Black; N A Martin; S N Sykes; J M Bronstein; L Jouben-Steele; P S Mischel; A Belldegrun; T F Cloughesy
Journal:  Neurosurg Focus       Date:  2000-12-15       Impact factor: 4.047

6.  Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes.

Authors:  A E Sloan; R Dansey; L Zamorano; G Barger; C Hamm; F Diaz; R Baynes; G Wood
Journal:  Neurosurg Focus       Date:  2000-12-15       Impact factor: 4.047

7.  Generation of cytotoxic immune responses against a rat glioma by in vivo priming and secondary in vitro stimulation with tumor cells.

Authors:  F P Holladay; G Lopez; M De; R A Morantz; G W Wood
Journal:  Neurosurgery       Date:  1992-04       Impact factor: 4.654

8.  Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: a six-year clinical experience.

Authors:  P Riva; G Franceschi; A Arista; M Frattarelli; N Riva; A M Cremonini; G Giuliani; M Casi
Journal:  Cancer       Date:  1997-12-15       Impact factor: 6.860

Review 9.  Glioma immunology and immunotherapy.

Authors:  I F Parney; C Hao; K C Petruk
Journal:  Neurosurgery       Date:  2000-04       Impact factor: 4.654

10.  A protocol for generation of clinical grade mRNA-transfected monocyte-derived dendritic cells for cancer vaccines.

Authors:  L J Mu; G Gaudernack; S Saebøe-Larssen; H Hammerstad; A Tierens; G Kvalheim
Journal:  Scand J Immunol       Date:  2003-11       Impact factor: 3.487
View more
  7 in total

Review 1.  Cellular immunotherapy for malignant gliomas.

Authors:  Yi Lin; Hideho Okada
Journal:  Expert Opin Biol Ther       Date:  2016-07-29       Impact factor: 4.388

Review 2.  Dendritic cell vaccines for brain tumors.

Authors:  Won Kim; Linda M Liau
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

Review 3.  Combating immunosuppression in glioma.

Authors:  Eleanor A Vega; Michael W Graner; John H Sampson
Journal:  Future Oncol       Date:  2008-06       Impact factor: 3.404

4.  DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.

Authors:  Wim Maes; Georgina Galicia Rosas; Bert Verbinnen; Louis Boon; Steven De Vleeschouwer; Jan L Ceuppens; Stefaan W Van Gool
Journal:  Neuro Oncol       Date:  2009-03-31       Impact factor: 12.300

Review 5.  Brain Tumor Immunotherapy: What have We Learned so Far?

Authors:  Stefaan Willy Van Gool
Journal:  Front Oncol       Date:  2015-06-17       Impact factor: 6.244

Review 6.  Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response.

Authors:  Joost Dejaegher; Stefaan Van Gool; Steven De Vleeschouwer
Journal:  Immunotargets Ther       Date:  2014-03-13

7.  Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study.

Authors:  S Rutkowski; S De Vleeschouwer; E Kaempgen; J E A Wolff; J Kühl; P Demaerel; M Warmuth-Metz; P Flamen; F Van Calenbergh; C Plets; N Sörensen; A Opitz; S W Van Gool
Journal:  Br J Cancer       Date:  2004-11-01       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.